1-3 of 3
Aisha Shamas-Din
Close
Sort by
Journal Articles

Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML

Sanduni U. Liyanage, Rose Hurren, Veronique Voisin, Gaëlle Bridon, Xiaoming Wang, ChangJiang Xu, Neil MacLean, Thirushi P. Siriwardena, Marcela Gronda, Dana Yehudai, Shrivani Sriskanthadevan, Daina Avizonis, Aisha Shamas-Din, Mark D. Minden, Gary D. Bader, Rebecca Laposa, Aaron D. Schimmer
Journal: Blood
Blood (2017) 129 (19): 2657–2666.
https://doi.org/10.1182/blood-2016-10-741207
Published: 2017
Includes: Supplemental data
Journal Articles

Leveraging Increased Nucleoside Kinase Activity to Selectively Deplete Mitochondrial DNA (mtDNA), Impair Oxidative Phosphorylation, and Target AML Cells

Sanduni U. Liyanage, Hon. B. Sc., Rose Hurren, Veronique Voisin, Wang Xiaoming, Gaëlle Bridon, Changjiang Xu, Neil MacLean, Thirushi Siriwardena, Aisha Shamas-Din, PhD, Shrivani Sriskanthadevan, Mark D. Minden, MD PhD, Gary D Bader, Rebecca Laposa, Aaron D. Schimmer, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1573.
https://doi.org/10.1182/blood.V128.22.1573.1573
Published: 2016
Journal Articles

The Highly Potent Bromodomain (BRD) Inhibitor FV-281 Displays Preclinical Efficacy in Acute Myeloid Leukemia (AML)

Zezhou Wang, PhD, Peter Dove, Aisha Shamas-Din, PhD, Rose Hurren, Xiaoming Wang, Neil MacLean, Marcela Gronda, Feng Bo, Janessa Li, Clarissa Skorupski, Wissam Hadri, David O'Neill, PhD, Ahmed Aman, PhD, Rima Al-awar, PhD, Mark D. Minden, MD PhD, Malik Slassi, PhD, Aaron D. Schimmer, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1364.
https://doi.org/10.1182/blood.V126.23.1364.1364
Published: 2015